Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus PULMOTECH MAA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus PULMOTECH MAA.
MPI DMSA KIDNEY REAGENT vs PULMOTECH MAA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
PULMOTECH MAA is a biologic agent that selectively inhibits the interleukin-5 (IL-5) signaling pathway by binding to the IL-5 receptor alpha subunit on the surface of eosinophils, thereby blocking eosinophil maturation, activation, and survival. This reduces eosinophil-mediated inflammation in the airways.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
4 mg IV every 6 hours; administer over 30 minutes.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal elimination half-life is 12 ± 3 hours. In elderly patients (>70 years) or severe renal impairment (CrCl <30 mL/min), half-life extends to 20-24 hours, requiring dose adjustment.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal excretion accounts for 65% (20% unchanged, 45% as metabolites); biliary/fecal excretion accounts for 30% (primarily conjugates); 5% exhaled as CO2.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical